CA3176525C - Antibody-mediated neutralization of chikungunya virus - Google Patents

Antibody-mediated neutralization of chikungunya virus

Info

Publication number
CA3176525C
CA3176525C CA3176525A CA3176525A CA3176525C CA 3176525 C CA3176525 C CA 3176525C CA 3176525 A CA3176525 A CA 3176525A CA 3176525 A CA3176525 A CA 3176525A CA 3176525 C CA3176525 C CA 3176525C
Authority
CA
Canada
Prior art keywords
antigen
monoclonal antibody
binding fragment
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3176525A
Other languages
English (en)
French (fr)
Other versions
CA3176525A1 (en
Inventor
James E. Crowe, Jr.
Scott A. Smith
Terence DERMODY
Laurie SILVA
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to CA3176525A priority Critical patent/CA3176525C/en
Publication of CA3176525A1 publication Critical patent/CA3176525A1/en
Application granted granted Critical
Publication of CA3176525C publication Critical patent/CA3176525C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
CA3176525A 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus Active CA3176525C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3176525A CA3176525C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14
US62/147,354 2015-04-14
CA3176525A CA3176525C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus
CA2982491A CA2982491C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2982491A Division CA2982491C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Publications (2)

Publication Number Publication Date
CA3176525A1 CA3176525A1 (en) 2016-10-20
CA3176525C true CA3176525C (en) 2026-04-21

Family

ID=57126199

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3176525A Active CA3176525C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus
CA2982491A Active CA2982491C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2982491A Active CA2982491C (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Country Status (27)

Country Link
US (2) US10787503B2 (enExample)
EP (1) EP3283101A4 (enExample)
JP (3) JP6979875B2 (enExample)
KR (2) KR102541905B1 (enExample)
CN (2) CN114478756B (enExample)
AR (1) AR104264A1 (enExample)
AU (2) AU2016250188C1 (enExample)
CA (2) CA3176525C (enExample)
CL (1) CL2017002596A1 (enExample)
CO (1) CO2017010316A2 (enExample)
CR (2) CR20210438A (enExample)
DO (1) DOP2017000236A (enExample)
EA (1) EA037060B1 (enExample)
EC (1) ECSP17075750A (enExample)
HK (1) HK1246671A1 (enExample)
IL (2) IL290449B2 (enExample)
MA (1) MA41517A (enExample)
MX (2) MX2017013286A (enExample)
MY (1) MY191666A (enExample)
NZ (1) NZ736445A (enExample)
PE (2) PE20180171A1 (enExample)
PH (2) PH12021500048A1 (enExample)
SG (2) SG11201708152SA (enExample)
TN (1) TN2017000438A1 (enExample)
TW (2) TWI772257B (enExample)
UA (1) UA125206C2 (enExample)
WO (1) WO2016168417A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2019236875A1 (en) * 2018-06-06 2019-12-12 Albert Einstein College Of Medicine, Inc. Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (en) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Hyperimmune globulins for treatment of chikungunya virus infections
CN118956771A (zh) * 2024-04-24 2024-11-15 华南农业大学 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用
WO2026039731A1 (en) * 2024-08-15 2026-02-19 The Board Of Regents Of The University Of Texas System Antibody genetics of radiologically isolated syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716145B1 (pt) * 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
CA2598966A1 (en) * 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9441032B2 (en) * 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP3021868A4 (en) 2013-07-19 2017-03-01 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof
US11286295B2 (en) * 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Also Published As

Publication number Publication date
CO2017010316A2 (es) 2017-12-15
US10787503B2 (en) 2020-09-29
CR20210438A (es) 2021-10-04
TW202248210A (zh) 2022-12-16
IL290449B1 (en) 2023-12-01
KR20230087616A (ko) 2023-06-16
KR102736152B1 (ko) 2024-11-28
CA3176525A1 (en) 2016-10-20
CR20170518A (es) 2018-01-25
AU2022202819A1 (en) 2022-05-19
WO2016168417A2 (en) 2016-10-20
EA201792220A1 (ru) 2018-03-30
CN107708726A (zh) 2018-02-16
JP2022174144A (ja) 2022-11-22
TW201643189A (zh) 2016-12-16
NZ736445A (en) 2023-06-30
TN2017000438A1 (en) 2019-04-12
NZ775007A (en) 2024-08-30
IL254891A0 (en) 2017-12-31
JP2021144047A (ja) 2021-09-24
ECSP17075750A (es) 2018-02-28
IL290449A (en) 2022-04-01
IL254891B (en) 2022-03-01
CA2982491C (en) 2023-08-29
CA2982491A1 (en) 2016-10-20
BR112017021952A2 (en) 2018-07-10
US20180079802A1 (en) 2018-03-22
US11345743B2 (en) 2022-05-31
MX2017013286A (es) 2018-06-19
MX2021013207A (es) 2021-12-10
WO2016168417A3 (en) 2017-01-05
CN107708726B (zh) 2022-01-14
AU2016250188B2 (en) 2022-02-03
JP2018520334A (ja) 2018-07-26
JP7536059B2 (ja) 2024-08-19
KR102541905B1 (ko) 2023-06-12
AU2022202819B2 (en) 2024-09-12
KR20180004403A (ko) 2018-01-11
US20200277359A1 (en) 2020-09-03
SG11201708152SA (en) 2017-11-29
SG10202107295XA (en) 2021-08-30
EP3283101A2 (en) 2018-02-21
PE20180171A1 (es) 2018-01-22
TWI772257B (zh) 2022-08-01
AR104264A1 (es) 2017-07-05
DOP2017000236A (es) 2017-12-15
JP6979875B2 (ja) 2021-12-15
PH12021500048A1 (en) 2022-05-11
PH12017501865A1 (en) 2018-03-05
CN114478756B (zh) 2024-08-23
CL2017002596A1 (es) 2018-05-18
CN114478756A (zh) 2022-05-13
MY191666A (en) 2022-07-06
AU2022202819C1 (en) 2025-04-03
AU2016250188C1 (en) 2022-08-11
EA037060B1 (ru) 2021-02-01
MA41517A (fr) 2017-12-19
TWI854285B (zh) 2024-09-01
HK1246671A1 (zh) 2018-09-14
PE20220297A1 (es) 2022-03-07
EP3283101A4 (en) 2019-01-16
AU2016250188A1 (en) 2017-11-02
IL290449B2 (en) 2024-04-01
UA125206C2 (uk) 2022-02-02

Similar Documents

Publication Publication Date Title
US11345743B2 (en) Antibody-mediated neutralization of chikungunya virus
US11054423B2 (en) Antibody-mediated neutralization of ebolaviruses
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US11851478B2 (en) Antibody-mediated neutralization of chikungunya virus
HK40072444B (en) Antibody-mediated neutralization of chikungunya virus
HK40072444A (en) Antibody-mediated neutralization of chikungunya virus
BR112017021952B1 (pt) Anticorpo monoclonal recombinante, seus usos, composição farmacêutica, métodos para produção do dito anticorpo bem como para detecção de uma infecção com vírus chikungunya em um indivíduo, e kit
BR122021008171B1 (pt) Anticorpo monoclonal recombinante, seu uso e método de produção, composição farmacêutica, kit e método de detecção de uma infecção com vírus chikungunya em um indivíduo
Spike Antigenic and Immunogenic

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250307

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250307

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250724

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251118

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260407

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260417

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260421